Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab with or without cemiplimab in advanced malignancies
2017-002846-61Phase 2Unknown
- Sponsor
- Sanofi
- Start
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab and cemiplimab in metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC) and advanced cancer (2 arms), sponsored by Sanofi. Primary endpoint: Dose limiting toxicities. Status: unknown.
02
Drugs
isatuximabcemiplimab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)non-small cell lung cancer (NSCLC)advanced cancer
Beyond the preview
Go deeper on 2017-002846-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002846-61.